Stockreport

Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

Natera, Inc.  (NTRA) 
Last natera, inc. earnings: 2/26 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.natera.com
PDF Interventional trial validates adaptive Signatera-guided treatment approach, achieving strong 63% response rate while reducing chemotherapy exposure in 74% of patientsRe [Read more]